Bausch + Lomb Renews Commitment to Glaucoma Awareness and Research

Bausch + Lomb, a leading eye health company, has launched its annual glaucoma awareness and fundraising initiatives for 2026, continuing its long-standing commitment to combating the progressive eye disease. The company's efforts include partnerships with prominent organizations in the field and support for innovative research and treatment options.

Fundraising Challenge and Awareness Campaigns

Bausch + Lomb has partnered with the Glaucoma Research Foundation (GRF) for its fifth annual fundraising challenge. Throughout January, which is recognized as Glaucoma Awareness Month, the company will match every dollar raised by GRF, up to $20,000, to support glaucoma research.

In addition to the fundraising effort, Bausch + Lomb is sponsoring The Glaucoma Foundation's social media campaign. This initiative aims to raise awareness about glaucoma and its impact by highlighting personal stories from patients and advocates. The campaign emphasizes the importance of early detection in managing the disease.

These awareness efforts build on the company's previous "Faces of Glaucoma" campaigns in 2024 and 2025, which showcased how glaucoma affects individuals across various demographics.

Advancements in Glaucoma Treatment

Bausch + Lomb continues to invest in expanding its portfolio of glaucoma treatments. In 2024, the company acquired Elios Vision for $99 million upfront, gaining access to a minimally invasive glaucoma surgery procedure that utilizes an excimer laser. The company projects peak sales of $175 million for this technology.

Furthermore, Bausch + Lomb is developing BL1107, an alpha-2B agonist eye drop that has shown promising results in phase 2 trials. The company believes this medication could improve upon existing treatments such as brimonidine and timolol, potentially becoming the new standard of care for glaucoma patients.

Industry Impact and Future Outlook

Bausch + Lomb's continued focus on glaucoma awareness and treatment development underscores the significant impact of this chronic eye condition on public health. As the company advances its research and expands its product offerings, it aims to improve outcomes for the millions of individuals affected by glaucoma worldwide.

The combination of awareness campaigns, fundraising efforts, and innovative treatment options demonstrates Bausch + Lomb's multifaceted approach to addressing the challenges posed by glaucoma. As the industry moves forward, collaborations between pharmaceutical companies and research foundations are likely to play an increasingly crucial role in combating this sight-threatening disease.